Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Liposomal Irinotecan and 5-FU Versus Irinotecan / Irinotecan+5-fluorouracil as Second-line Therapy for Patients With Esophageal Squamous Cell Carcinoma: A Open-label, Randomized Study

NCT06501664 is registered in ClinicalTrials.gov with Rui-hua Xu, MD, PhD as lead sponsor.

NCT NCT06501664
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06501664 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Liposomal Irinotecan and 5-FU Versus Irinotecan / Irinotecan+5-fluorouracil as Second-line Therapy for Patients With Esophageal Squamous Cell Carcinoma: A Open-label, Randomized Study
Lead sponsor
Rui-hua Xu, MD, PhD
Phase
Phase 3
Overall status
Not yet recruiting
Start date
August 1, 2024
Completion date
November 30, 2027
Enrollment
360 (estimated)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

esophageal cancer